HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Oliver McCallion *Translational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-5977-812X
Weijie Du *Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Viktor Glaser *Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Kate MilwardTranslational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-3019-4443
Sarah ShortTranslational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-7594-7915
Merve BiliciTranslational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Amy CrossTranslational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Helen StarkTranslational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-9360-9864
Clemens FrankeBerlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0009-0009-0476-2807
Jonas KathBerlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0001-7721-7978
Mikhail ValkovBerlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Mingxing YangBIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
Leila AminiBerlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-4855-5905
Annette KünkeleBerlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-8406-5412
Julia K PolanskyBIH-Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-4727-2540
Michael Schmueck-HenneresseBerlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0001-5964-9179
Hans-Dieter VolkBerlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-7743-6668
Petra ReinkeBerlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-0771-4375
Dimitrios L WagnerBerlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. dimitrios-l.wagner@charite.de.ORCID http://orcid.org/0000-0002-2189-3579
Joanna HesterTranslational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. joanna.hester@nds.ox.ac.uk.ORCID http://orcid.org/0000-0002-7466-3849
Fadi IssaTranslational Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. fadi.issa@nds.ox.ac.uk.ORCID http://orcid.org/0000-0002-8279-7732
Funding
British Heart Foundation (BHF) FS/ 12/72/29754EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 825392Wellcome TrustWellcome Trust (Wellcome) 211122/Z/18
6 · The paper itself
Abstract
Regulatory T cells (Tregs) hold promise for treating autoimmune disease and transplant rejection, yet generation of autologous products for adoptive transfer can suffer donor variability and slow turnaround, limiting their use in urgent indications. We therefore examine whether allogeneic, pre-manufactured ('off-the-shelf') Tregs could overcome these barriers. In a human skin-xenograft model, HLA-mismatched Tregs are swiftly eliminated by recipient CD8
Indexed as
Histocompatibility Antigens Class IT-Lymphocytes, RegulatoryAdoptive TransferAnimalsCD8-Positive T-LymphocytesCRISPR-Cas SystemsForkhead Transcription FactorsGene EditingGraft SurvivalHumansMiceSkin TransplantationTransplantation, HomologousForkhead Transcription FactorsHistocompatibility Antigens Class I
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model. · full record | OpenQuestion